Thalidomide
- Generic Name
- Thalidomide
- Brand Names
- Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed
- Drug Type
- Small Molecule
- Chemical Formula
- C13H10N2O4
- CAS Number
- 50-35-1
- Unique Ingredient Identifier
- 4Z8R6ORS6L
- Background
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators li...
- Indication
Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).
- Associated Conditions
- Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma
- Associated Therapies
- -
Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma
- First Posted Date
- 2016-04-11
- Last Posted Date
- 2020-04-01
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT02733380
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, ZhengZhou, Henan, China
Thalidomide Plus Chemotherapy Versus Chemotherapy Alone for Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2016-01-07
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT02649101
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS
- Conditions
- Interventions
- First Posted Date
- 2015-10-26
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Mario Boccadoro
- Target Recruit Count
- 175
- Registration Number
- NCT02586038
- Locations
- 🇮🇹
AO SS Antonio e Biagio e Cesare Arrigo di Alessandria, Alessandria, Italy
Modified Bortezomib-based Combination Therapy for Multiple Myeloma
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2018-05-04
- Target Recruit Count
- 80
- Registration Number
- NCT02559154
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, China
A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2015-09-10
- Last Posted Date
- 2021-04-15
- Lead Sponsor
- University College, London
- Target Recruit Count
- 10
- Registration Number
- NCT02545907
- Locations
- 🇬🇧
Derriford Hospital, Plymouth, Devon, United Kingdom
🇬🇧Royal Bournemouth General Hospital, Bournemouth, Dorset, United Kingdom
🇬🇧Southampton General Hospital, Southampton, Hampshire, United Kingdom
Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165
- First Posted Date
- 2015-07-23
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 2
- Registration Number
- NCT02507336
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Thalidomide in Treating Crohn's Disease
- First Posted Date
- 2015-07-17
- Last Posted Date
- 2016-03-01
- Target Recruit Count
- 47
- Registration Number
- NCT02501291
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
The Effects of Huang-Lian-Jie-Du-Tang（HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy
- First Posted Date
- 2015-06-10
- Last Posted Date
- 2015-06-10
- Lead Sponsor
- Wuhan University
- Target Recruit Count
- 500
- Registration Number
- NCT02467647
- Locations
- 🇨🇳
Wuhan University, Wuhan, Hubei, China
Optimising Renal Outcome in Myeloma Renal Failure
- Conditions
- Interventions
- First Posted Date
- 2015-04-23
- Last Posted Date
- 2022-01-27
- Lead Sponsor
- Oxford University Hospitals NHS Trust
- Target Recruit Count
- 31
- Registration Number
- NCT02424851
- Locations
- 🇬🇧
Kent & Canterbury Hospital, Canterbury, United Kingdom
🇬🇧Royal Liverpool Hospital, Liverpool, United Kingdom
🇬🇧Heartlands Hospitals, Birmingham, United Kingdom
Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2015-04-08
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Target Recruit Count
- 90
- Registration Number
- NCT02410694
- Locations
- 🇦🇹
UK Innsbruck, Universitätsklinik für Innere Medizin, Klinische Abteilung für Hämatologie und Onkologie, Innsbruck, Tirol, Austria
🇨🇿Faculty Hospital Brno and Faculty of Medicine MU Brno 2nd Internal Clinic, Brno, Czechia
🇨🇿Fakultní nemocnice Ostrava, Ostrava-Poruba, Czechia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.